Abstract
Background Japanese encephalitis virus (JEV) is a major threat to human health. Bangladesh is considering introducing a JEV vaccine, however, the investment case is hampered by a poor understanding of key aspects of JEV ecology, including underlying patterns of infection, the infection fatality ratio, and which host and vectors maintain transmission.
Methods We conducted a seroprevalence study in individuals of all ages in Chapai Nawabganj, Bangladesh. We tested blood samples for anti-JEV antibodies using a novel assay that limits cross-reactivity with dengue virus, trapped mosquitoes, and collected information about potential host species. We combined our results with data from a pig census, human case data and healthcare seeking patterns, all from the same region, and used mathematical models to recover risk factors for infection, and underlying probabilities of severe disease and death.
Findings We found 14.3% (203/1455) of participants had antibodies against JEV. We estimated 0.5% of the susceptible population gets infected each year, however, infection risk was spatially heterogeneous, with the presence of pigs in the vicinity being the most important predictor of seropositivity. We identified 10 different known mosquito vectors for JEV. We estimated that 1 in 1,000 infections result in severe disease, 1 in 10,000 result in death, and 76% of severe cases are missed by surveillance systems.
Interpretation JEV infection risk is highly spatially heterogeneous, with the underlying potential of vaccines linked to the distribution of pig-raising communities.
Funding Centers for Disease Control and Prevention (CDC)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the CDC. MPD is funded by the Gates Cambridge Trust (OPP1144), HS was funded by the ERC (804744), SC acknowledges financial support from Labeix IBEID (Grant ANR-10-LABX-62-IBEID), the European Union Horizon 2020 research and innovation programme under VEO grant agreement (874735).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethical review boards at Centers for Disease Prevention and Control, International Centre for Diarrheal Diseases Research Bangladesh, Johns Hopkins Bloomberg School of Public Health, and Institut Pasteur. Informed consent, and assent when appropriate, was obtained from all individuals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Joint senior authors
Data Availability
Data and source code to reproduce analyses will be available at https://github.com/marianaperezduque.
